Regeneron Pharmaceuticals Inc

Most Recent

  • Intellia scientist in lab working on CRISPR technology
    News

    CRISPR Stocks Are Soaring Amid Biotech Breakthrough

    By Rachel Curry
  • uploads///Graph
    Company & Industry Overviews

    Analysts’ Recommendations for United Therapeutics

    In 2Q17, United Therapeutics (UTHR) reported revenue of ~$445 million, representing year-over-year growth of around 8%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Analysts’ Recommendations for Regeneron and Peers in June 2017

    On March 28, 2017, Regeneron and Sanofi’s Dupixent secured FDA approval as an injectable treatment for patients suffering from moderate-to-severe eczema.

    By Margaret Patrick
  • uploads///Chart
    Earnings Report

    A Look at Ionis’s Revenue Streams in the Second Quarter

    Ionis Pharmaceuticals (IONS) reported year-over-year (or YoY) growth of 5% in revenues to $118 million during Q2 2018 as compared to the revenues of $112 million during the second quarter of 2017.

    By Mike Benson
  • uploads///graph_
    Company & Industry Overviews

    Analysts’ Recommendations for Mylan in September 2017

    In 2Q17, Mylan reported revenues close to $3.0 billion, which is a YoY rise of around 16.0%, mainly driven by increased sales in Europe and the Rest of World markets.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Restricted Access Continues to Impact Praluent Sales in 2016

    Praluent is one of the Regeneron’s key new additions in the cardiovascular segment. It’s a PCSK9 therapy approved for lowering LDL cholesterol in patients.

    By Margaret Patrick
  • uploads///REGN Eylea Sales
    Company & Industry Overviews

    Taking Stock of Regeneron Pharmaceuticals’ Marketed Products

    Globally, Regeneron Pharmaceuticals’ (REGN) Eyelea generated $5.9 billion in sales in fiscal 2017 compared with $5.1 billion in fiscal 2016.

    By Kenneth Smith
  • uploads///Relative valuation
    Earnings Report

    Regeneron Continues to Trade at Premium

    Regeneron is consistently trading at a premium compared to its peers. As of January 22, it was trading at a valuation multiple of 26.67x its earnings.

    By Jillian Dabney
  • uploads///Analysts Ratings
    Company & Industry Overviews

    What Analysts Recommend for Celgene in 2017

    Celgene (CELG) has a focused and robust clinical pipeline that may help it launch new drugs in the future.

    By Daniel Collins
  • uploads///Eylea
    Earnings Report

    Eylea’s Net Sales in the US Jumped in 4Q15, but Was It High Enough?

    Eylea, the leading product in Regeneron Pharmaceuticals’s (REGN) portfolio, fetched $746 million during the fourth quarter of 2015 in the US.

    By Jillian Dabney
  • uploads///Graph
    Miscellaneous

    Bristol-Myer Squibb’s Opdivo Is Keytruda’s Strong Competitor

    the U.S. Food and Drug Administration accepted the filing of a supplemental Biologics License Application for Bristol-Myers Squibb’s Opdivo.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Amgen Continues to Be Confident in Repatha in 2017

    In 1Q17, Amgen’s (AMGN) PCSK9 inhibitor therapy, Repatha, reported revenue of nearly $49 million. The drug earned $33 million in revenue in US markets and $16 million in international revenue.

    By Margaret Patrick
  • uploads///Part  Graph
    Company & Industry Overviews

    XBI’s Large Caps: BioMarin Gives Update on Gene Therapy Study

    The large-cap stocks of the SPDR S&P Biotech ETF (XBI) rose 0.3% on April 20, 2016. Large-cap stocks account for 19.3% of XBI’s portfolio.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    SPDR S&P Biotech ETF (XBI) Had a Mixed Day on October 8

    The SPDR S&P Biotech ETF (XBI) had a mixed day on October 8, 2015. Of the 101 holdings, 32 stocks ended up in green, and 69 stocks ended up in red. But overall, XBI fell 1.0% for the day.

    By Peter Neil
  • uploads///dna _
    Company & Industry Overviews

    A Look at Incyte’s Valuation as of May 25

    Incyte reported EPS of -$0.19 on revenue of $382.3 million in Q1 2018 compared to revenue of $384.1 million in Q1 2017.

    By Mike Benson
  • uploads///cure _
    Company & Industry Overviews

    Teva Stock Continues to Trend Higher on Positive News

    Teva Pharmaceutical Industries (TEVA) has risen ~9% over the last five days.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Why Eylea Could Face Tough Competition in 2016

    In 2016, Regeneron expects to face increased competition from Roche Holding’s Lucentis (Ranibizumab) and Avastin (Bevacizumab) for Eylea.

    By Margaret Patrick
  • uploads///virus infected cells _
    Company & Industry Overviews

    Ionis Pharmaceuticals’ Valuation on May 23

    Ionis Pharmaceuticals (IONS), a leading therapeutics company, develops and markets drugs for life-threatening diseases.

    By Mike Benson
  • uploads///Graph
    Earnings Report

    Will Regeneron’s Revenue Surpass Analysts’ Estimates in 1Q17?

    In 2017, Regeneron expects its eye drug, Eylea, to witness single-digit revenue growth on a year-over-year basis. Eylea has continued to be the company’s major revenue driver in the year.

    By Margaret Patrick
  • uploads///revenue projections
    Company & Industry Overviews

    BioMarin to Cross $1 Billion Revenue in 2016

    BioMarin Pharmaceutical (BMRN) expects its existing commercialized drugs to add $1.1 billion and $1.2 billion to its top line in 2016.

    By Jillian Dabney
  • uploads///ANR
    Earnings Report

    BioMarin: Why So Many ‘Buy’ Recommendations?

    BioMarin (BMRN) is expected to report 2Q16 earnings on August 4, 2016. “Buy” ratings have increased to 94.7% from 90% on June 29, 2016.

    By Jillian Dabney
  • uploads///Eylea sales
    Earnings Report

    Worst-Case Scenario for Regeneron: What If Eylea Sales Slow Down by 2018?

    Regeneron Pharmaceuticals (REGN) depends heavily upon its key drug, Eylea, which recorded global sales of $4.1 billion during fiscal 2015.

    By Jillian Dabney
  • uploads///Graph
    Earnings Report

    What Do Analysts Recommend for United Therapeutics?

    23.1% of analysts gave United Therapeutics (UTHR) a “buy” recommendation while 69.2% of analysts rated the company a “hold.”

    By Margaret Patrick
  • uploads///Eylea
    Company & Industry Overviews

    How Regeneron Is Working to Maintain Eylea’s Dominance

    Regeneron’s (REGN) flagship product, Eylea (Aflibercept), was launched in the US in November 2011.

    By Jillian Dabney
  • uploads///Part  Graph
    Company & Industry Overviews

    Regeneron’s Stock Reacts to Dupilumab Phase 3 Trials

    Regeneron Pharmaceuticals (REGN) rose 9.3% during the week ending April 1, 2016.

    By Peter Neil
  • uploads///approved _
    Company & Industry Overviews

    FDA Approves Teva’s Generic Version of EpiPen, Stock Up 7.5%

    Teva Pharmaceutical Industries (TEVA) received FDA approval for the generic version of Mylan’s (MYL) allergy products EpiPen and EpiPen Jr.

    By Sarah Collins
  • uploads///REGN
    Energy & Utilities

    Viking Global buys a new stake in Regeneron Pharmaceuticals

    Viking Global Investors revealed a brand new position valued at around $315 million in Regeneron Pharmaceuticals (REGN) last quarter. The position accounts for 1.32% of Viking’s total portfolio.

    By Samantha Nielson
  • uploads/// Revenue growth
    Healthcare

    The IBB Biotechnology ETF: The Drugs You Need?

    The iShares NASDAQ Biotechnology ETF (IBB) aims to track the investment results of the NASDAQ Biotechnology Index, which comprises NASDAQ-listed biotechnology and pharmaceuticals companies.

    By Peter Barnes
  • uploads///share price
    Earnings Report

    Understanding Regeneron’s Share Price Movement after Its 4Q15 Results

    Regeneron Pharmaceuticals (REGN) earned $1.1 billion in 4Q15, which translates to a 37% YoY (year-over-year) sales growth.

    By Jillian Dabney
  • uploads///Graph
    Earnings Report

    Factors That Will Determine Repatha’s Future Commercial Success

    Amgen (AMGN) believes that Repatha will be widely accepted as a major cardiovascular therapy for high-risk patients.

    By Margaret Patrick
  • uploads///Dupixent
    Company & Industry Overviews

    Regeneron’s Dupixent Approved for Atopic Dermatitis

    In March 2017, the US Food and Drug Administration (FDA) approved Sanofi’s (SNY) and Regeneron Pharmaceuticals’ (REGN) Dupixent (dupilumab) for the treatment of individuals with moderate-to-severe atopic dermatitis.

    By Daniel Collins
  • uploads///Eylea
    Earnings Report

    What Drove Regeneron’s 3Q16 Performance?

    In fiscal 3Q16, Regeneron Pharmaceuticals (REGN) recorded revenue amounting to $1.2 billion and net product sales amounting to $857 million.

    By Jillian Dabney
  • uploads///Graph Autosomal recessive pattern
    Company & Industry Overviews

    BioMarin Leads in the Market for Mucopolysaccharidoses Disorders

    BioMarin holds three drugs in its portfolio indicated for different types of mucopolysaccharidoses disorders. They are Vimizim, Naglazyme, and Aldurazyme.

    By Jillian Dabney
  • uploads///dupixent sales
    Company & Industry Overviews

    Sanofi’s Dupixent: Growth Prospects and Phase 3 Trials

    Sanofi and Regeneron are conducting clinical studies for the treatment of a range of type 2 inflammation conditions with Dupixent.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Dupixent May Be Strong Growth Driver for Sanofi in the Future

    Regeneron (REGN) and Sanofi’s (SNY) Dupixent has seen stronger total prescription (or TRx) performance since its launch than Cosentyx, the dermatology biologic drug by Novartis (NVS).

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    The Latest on Fasinumab, a Teva-Regeneron Collaborative Drug

    On October 17, 2016, Teva and Regeneron announced that the FDA had placed the Phase 2 study for fasinumab on clinical hold.

    By Margaret Patrick
  • uploads///Eylea
    Company & Industry Overviews

    Eylea Could Continue to Generate High Revenue

    Regeneron Pharmaceuticals (REGN) markets Eylea in the United States, and Bayer (BAYZF) commercializes the drug outside the US market.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Repatha Represents a Solid Growth Opportunity for Amgen in 2017

    Despite Amgen’s efforts to improve access for Repatha, the drug has seen high rejection rates in the US due to stringent preauthorization requirements.

    By Margaret Patrick
  • uploads///ILMN
    Energy & Utilities

    Why did Halvorsen’s Viking Global boost its position in Illumina?

    Viking Global Investors significantly increased its position in Illumina (ILMN) last quarter. The position, which accounted for 0.88% of Viking’s total 4Q 2013 portfolio, is now the fund’s third largest position, at 5.53% of the 1Q 2014 portfolio.

    By Samantha Nielson
  • uploads///Part  Graph
    Company & Industry Overviews

    Why Biogen’s Stock Price Has Fallen

    Biogen (BIIB) was the worst-performing stock within the Health Care Select Sector SPDR ETF (XLV) on June 7, 2016.

    By Peter Neil
  • uploads///Repatha and Blincyto
    Company & Industry Overviews

    Amgen’s Repatha and Blincyto: How They Did in 3Q17

    In 4Q17, Amgen’s (AMGN) Repatha generated revenues of $98 million, which reflected a 69% growth YoY (year-over-year) and a 10% growth quarter-over-quarter.

    By Daniel Collins
  • eli lilly covid  treatments
    Healthcare

    Trump Pushes Regeneron and Eli Lilly Antibodies for COVID-19, Stocks Up

    By Ambrish Shah
  • Roche and Regeneron Partner on COVID-19 Drug
    Healthcare

    Regeneron to Partner With Roche on COVID-19 Drug

    By Ambrish Shah
  • uploads///Analysts ratings
    Company & Industry Overviews

    Gilead Sciences on the Street in January: Analyst Recommendations

    In December 2017, Gilead Sciences (GILD) and its subsidiary specialized in cell therapy, Kite, entered into an agreement with Cell Design Labs.

    By Daniel Collins
  • uploads///ANR
    Company & Industry Overviews

    Why Are Most Analysts Recommending a ‘Buy’ for Vertex?

    On February 16, 2016, after Vertex’s (VRTX) 4Q15 and fiscal 2015 earnings release, revised ratings showed that 76% of analysts now recommend a “buy” for Vertex stock.

    By Jillian Dabney
  • uploads///human skeleton _
    Earnings Report

    How Exelixis Is Positioned ahead of Its Q2 2018 Earnings Release

    Exelixis (EXEL) is scheduled to report its second-quarter earnings results on August 1.

    By Daniel Collins
  • uploads///PE multiple
    Company & Industry Overviews

    Why Is Vertex Pharmaceuticals’ Valuation at a Discount?

    On February 17, 2016, Vertex Pharmaceuticals (VRTX) was trading at a forward PE multiple of 15.20x. It’s trading at a discount when compared to peers Alexion (ALXN) and Regeneron (REGN).

    By Jillian Dabney
  • uploads///exe
    Earnings Report

    How Did Exelixis Perform in 1Q18?

    In 1Q18, Exelixis (EXEL) generated revenues of $212.3 million, compared to $80.89 million in 1Q17. In 1Q18, Exelixis witnessed ~77% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Part  Graph
    Company & Industry Overviews

    XLV Gains May 10, Trades above Its 20-Day Moving Average

    On May 10, 2016, the top gainers of XLV were Allergan (AGN) and Regeneron Pharmaceuticals (REGN). They rose by 5.3% and 2.8%, respectively.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    Incyte Was a Star Performer from August 10–17, 2015

    By market cap size, Incyte (INCY) is among the top ten holdings of the SPDR S&P Biotech ETF (XBI). Incyte has a weight of 1.22% in XBI’s portfolio.

    By Peter Neil
  • uploads///ANR
    Earnings Report

    What Can Investors Expect from Regeneron’s 4Q15 Earnings?

    Regeneron will report its earnings for 4Q15 and fiscal 2015 on February 9, 2016. It will report the earnings before the financial markets open in the US.

    By Jillian Dabney
  • Healthcare

    Amgen has attractive, high-growth assets

    The principal products represented 92% of Amgen’s worldwide product sales for the first half of 2014. Total product sales in 3Q14 rose 4% year-over-year, mainly driven by Kyprolis, Prolia, Neulasta, and Xgeva.

    By Samantha Nielson
  • uploads///Analysts recommendation
    Company & Industry Overviews

    What Amgen’s Analysts Recommend in August 2017

    Of the 24 analysts covering Amgen, four have recommended a “strong buy” for the stock, while six have recommended a “buy.”

    By Daniel Collins
  • uploads///AdobeStock_
    Earnings Report

    Regeneron Is Down despite Earnings Beat

    Regeneron (REGN) reported its Q2 earnings results before the markets opened. REGN reported revenues of $1.93 billion, a YoY increase of 20%.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Sanofi’s Immunology Portfolio in the First Quarter

    In the first quarter, Sanofi’s (SNY) Immunology Franchise reported net sales of 359 million euros.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Analyzing Sanofi’s Oncology Portfolio in the First Quarter

    In the first quarter, Sanofi’s (SNY) Oncology franchise reported net sales of 399 million euros, a YoY rise of 7.8% on a CER (constant exchange rate) basis.

    By Margaret Patrick
  • uploads///scientist _
    Company & Industry Overviews

    Analysts Raise Their Target Price for Regeneron in March

    Wall Street analysts expect a potential upside of 6.79% for Regeneron Pharmaceuticals based on the company’s closing price on March 27.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Are Teva Pharmaceutical’s Key Growth Drivers in 2019?

    On its fourth-quarter earnings conference call, Teva Pharmaceutical (TEVA) highlighted Ajovy and Austedo as its key growth drivers for 2019.

    By Margaret Patrick
  • uploads///SRPT
    Company & Industry Overviews

    Understanding Sarepta Therapeutics’ Operational Performance

    Sarepta Therapeutics’ (SRPT) R&D (research and development) expenses rose YoY (year-over-year) to $86.58 million.

    By Kenneth Smith
  • uploads///dna _
    Company & Industry Overviews

    Taking Stock of bluebird bio’s Performance

    In the third quarter, bluebird bio’s total revenue rose YoY (year-over-year) to $11.53 million from $7.71 million.

    By Kenneth Smith
  • uploads///REGN
    Company & Industry Overviews

    Do Analysts See Any Upside for Regeneron Stock?

    Of the 26 analysts covering Regeneron Pharmaceuticals (REGN), eight recommend “buy” or a higher rating, 17 recommend “hold,” and one recommends “sell.”

    By Kenneth Smith
  • uploads///REGN
    Company & Industry Overviews

    Regeneron Pharmaceuticals’ Gross Margin Trends

    In fiscal 2018 and fiscal 2019, Regeneron Pharmaceuticals (REGN) is expected to generate revenue of $6.49 billion and $7.16 billion, respectively, compared with revenue of $5.87 billion in fiscal 2017.

    By Kenneth Smith
  • uploads///Graph
    Company & Industry Overviews

    Austedo Is on Solid Growth Trajectory in 2018

    In the third quarter, Austedo reported revenues of $62 million, which is a YoY rise of 933.33% and a sequential rise of 40.91%.

    By Margaret Patrick
  • uploads///syringe _
    Company & Industry Overviews

    Jazz Pharmaceuticals: Analysts’ View in November

    On November 12, Jazz Pharmaceuticals’ stock price closed at $148.54, which represents ~2.04% growth from the close of $145.57 on November 9.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    Amgen: Analysts’ Recommendations on October 25

    Wall Street analysts expect Amgen’s (AMGN) revenues to decrease marginally by ~0.1% to $5.769 billion during the third quarter.

    By Mike Benson
  • uploads///blood _
    Earnings Report

    Alkermes in the Third Quarter: A Performance Overview

    Alkermes (ALKS) reported its third-quarter results on October 23. It generated net revenues of $248.7 million, a 14% YoY growth.

    By Daniel Collins
  • uploads///dna _
    Earnings Report

    Biogen Surpassed Estimates in Q3 2018, Reports Strong Growth

    Today, Biogen (BIIB) reported EPS of $7.40 on revenues of ~$3.44 billion. BIIB beat the EPS estimate of $6.78 on revenues of ~$3.33 billion.

    By Mike Benson
  • uploads///Part_Graph
    Company & Industry Overviews

    Regeneron and Alnylam Collaborate for NASH Research Program

    Alnylam Pharmaceuticals (ALNY) is currently trading 1.47% higher than its 52-week low price of $78.85 and 48.04% lower than its 52-week high price of $153.99.

    By Margaret Patrick
  • uploads///Part_Graph
    Company & Industry Overviews

    How Regeneron Stock Performed in the First Half of October

    On October 15, Regeneron (REGN) closed at $377.55, which was 1.72% lower than its previous closing price on October 12.

    By Margaret Patrick
  • uploads///Chart
    Earnings Report

    Biogen: Revenue Growth Is Expected in Q3

    Interferon contributed ~18% of Biogen’s total revenues. Analysts expect the revenues to decrease during the third quarter.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Ionis Pharmaceuticals’ Valuations on September 28

    Ionis reported revenues of $118.0 million during the second quarter for 5.0% growth in year-over-year revenues compared to the second quarter of 2017.

    By Mike Benson
  • uploads///dna _
    Company & Industry Overviews

    Ionis Pharmaceuticals’ Stock Performance in September

    On September 28, Ionis Pharmaceuticals received one “strong buy” rating, three “buy” ratings, seven “hold” ratings, and two “sell” ratings.

    By Mike Benson
  • uploads///product approval timeline
    Company & Industry Overviews

    Sanofi Eyes Market Expansion with Phase 3 Data for Dupixent

    On September 15, Sanofi and Regeneron announced Phase 3 data results for Dupixent for the treatment of moderate-to-severe atopic dermatitis.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    Shire’s Quarterly Revenue Trend

    Biotechnology company Shire (SHPG) reported a 4.6% YoY (year-over-year) rise in revenue to ~$3.9 billion in the second quarter.

    By Mike Benson
  • uploads///regenxbio ana reco
    Company & Industry Overviews

    Analyzing Regenxbio’s Valuation Metrics

    Regenxbio (RGNX) generated revenues of $40.03 million in the second quarter compared to $6.56 million in Q2 2017.

    By Kenneth Smith
  • uploads///Graph
    Company & Industry Overviews

    Why Vertex Is Expected to Report Robust EPS Growth in 2018

    Wall Street analysts have projected Vertex Pharmaceuticals’ fiscal 2018 adjusted diluted EPS to be around $3.8, which would be a YoY rise of approximately 93.1%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    OPKO Health Expects Its Loss per Share to Shrink This Year

    In the third quarter, OPKO Health (OPK) expects research and development expenses of $33 million–$38 million, and foresees its total operating expenses falling to $285 million–$305 million.

    By Margaret Patrick
  • uploads///medicine _
    Company & Industry Overviews

    OPKO Health’s Q3 2018 Revenue Expectations

    In the third quarter, OPKO Health (OPK) expects service revenue of $200 million–$220 million, assuming stable reimbursement rates and a small rise in volumes.

    By Margaret Patrick
  • uploads///ALNY
    Earnings Report

    What Does Alnylam Pharmaceuticals’ Valuation Trend Indicate?

    In August, of the 16 analysts covering Alnylam Pharmaceuticals, 13 have given the stock “buy” or higher ratings.

    By Kenneth Smith
  • uploads///ALNY
    Earnings Report

    What Alnylam Pharmaceuticals’ Bottom Line Trend Indicates

    Alnylam Pharmaceuticals’ interest income increased from $2.58 million in the second quarter of 2017 to $6.1 million in the second quarter of 2018.

    By Kenneth Smith
  • uploads///microscope _
    Earnings Report

    Sarepta Therapeutics’ Q2 2018 Earnings and Revenue Growth

    Sarepta Therapeutics (SRPT) released its Q2 2018 earnings on August 8, surpassing analysts’ estimates for EPS and revenues.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What’s Ionis Pharmaceuticals’ Valuation after Q2 Results?

    Ionis Pharmaceuticals (IONS), a leading RNA-targeted therapeutics developing company, aims to develop best-in-class drugs for life-threatening diseases.

    By Mike Benson
  • uploads///dna _
    Earnings Report

    What to Expect from Sarepta’s Second-Quarter Earnings

    Wall Street analysts estimate Sarepta’s revenues will increase by over 100% to $71.6 million in Q2 2018 as compared to revenues of $35.0 million during Q2 2017.

    By Mike Benson
  • uploads///drugs _
    Company & Industry Overviews

    Why Tonix Pharmaceuticals Stock Soared Today

    Today, Tonix Pharmaceuticals (TNXP) was trading at $4.23, which represents ~7.09% growth from yesterday’s close of $3.95.

    By Daniel Collins
  • uploads///syringe _
    Company & Industry Overviews

    Incyte’s Valuations on July 6

    Incyte (INCY) posted revenues of $382.3 million in Q1 2018, a marginal decrease in YoY revenues compared to $384.1 million in Q1 2017.

    By Mike Benson
  • uploads///dna _
    Company & Industry Overviews

    How Ionis Pharmaceuticals’ Valuation Compares

    Ionis Pharmaceuticals (IONS), a therapeutics development leader, commercializes products in collaboration with other pharmaceutical companies.

    By Mike Benson
  • uploads///syringe _
    Company & Industry Overviews

    Analysts Are Mostly Positive on Exelixis in July

    On July 3, Exelixis (EXEL) stock closed at $21.4, a ~15.7% increase from its 52-week low of $18.5 on May 10.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Pediatric Atopic Dermatitis Indication May Boost Dupixent Revenue

    A label expansion could further advance Dupixent’s position in the atopic dermatitis market.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Regeneron Focuses on Expanding Eylea’s Diabetic Retinopathy Label

    On March 19, Regeneron announced positive top line results from its Phase 3 PANORAMA trial.

    By Margaret Patrick
  • uploads///headache pain pills medication
    Company & Industry Overviews

    Solid Biosciences’ Stock Price Rose 46.6% on June 19

    On June 19, 2018, Solid Biosciences’ (SLDB) stock price rose ~46.6% to $43.00. On June 19, the stock price hit a 52-week high of $54.84.

    By Daniel Collins
  • uploads///GRaph
    Company & Industry Overviews

    Regeneron Is Expected to Witness a Modest Revenue Rise in 2018

    Regeneron (REGN) currently has six FDA-approved drugs and 17 investigational therapies in its research pipeline.

    By Margaret Patrick
  • uploads///ice cream cone _
    Basic Materials

    The Economy Is on a Roll, and It’s Bringing the Stock Market Along With It

    Jobs data released this morning shows that the U.S. economy is firing on all cylinders, and the stock market has responded by rallying.

    By JP Gravitt
  • uploads///ALNY
    Company & Industry Overviews

    Do Alnylam Pharmaceuticals’ Cash Flows Look Healthy?

    Since the beginning of 2018, the stock price of Alnylam Pharmaceuticals has dropped from $130 levels to $100 as of May 21.

    By Kenneth Smith
  • uploads///MEI
    Company & Industry Overviews

    What Led to MEI Pharma Stock’s 55% Rise Last Week?

    MEI Pharma (MEIP) saw a 55% rise in its stock price between May 11 and May 18.

    By Daniel Collins
  • uploads///Eylea
    Company & Industry Overviews

    How Did Regeneron’s Eylea, Kevzara, and Zaltrap Perform in 1Q18?

    In 1Q18, Eylea generated net global revenue of $1.6 billion compared to $1.3 billion in 1Q17.

    By Daniel Collins
  • uploads///Praluent
    Company & Industry Overviews

    How Regeneron’s Praluent and Dupixent Performed in 1Q18

    In 1Q18, Regeneron Pharmaceuticals’ (REGN) Praluent reported revenue of $60 million compared to $36 million in 1Q17.

    By Daniel Collins
  • uploads///Upadacitinib
    Company & Industry Overviews

    Upadacitinib Could Drive AbbVie’s Long-Term Growth

    In April 2018, AbbVie (ABBV) positive results for its Phase 3 SELECT-COMPARE trial, which evaluated the safety and efficacy of upadacitinib for adults with moderate-to-severe rheumatoid arthritis.

    By Daniel Collins
  • uploads///Praluent
    Fund Managers

    Exploring the Growth of Regeneron’s Praluent

    In April 2017, the FDA approved a supplemental biologics license application (or sBLA) for Praluent for a once-monthly dose.

    By Kenneth Smith
  • uploads///pill _
    Company & Industry Overviews

    Why Did Regeneron Pharmaceuticals’ Stock Price Rise Last Week?

    On March 28, 2018, Regeneron Pharmaceuticals (REGN) was trading at $344.36, a ~9.8% rise from its 52-week low of $313.53.

    By Daniel Collins
  • uploads///Dupixent
    Company & Industry Overviews

    Regeneron Pharmaceuticals’ Dupixent, Kevzara, and Zaltrap

    In 4Q17, Regeneron Pharmaceuticals’ (REGN) Dupixent generated revenues of $139.0 million compared to $88.9 million in 3Q17.

    By Daniel Collins
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.